fbpx Skip to main content

MONDAY, April 5, 2021 (HealthDay News) — For veterans with HIV and hypertension, the rate of cardiovascular disease (CVD) events is high and is increased in association with ß-blocker use, according to a study published online April 5 in Hypertension.

Leah B. Rethy, M.D., from the University of Pennsylvania in Philadelphia, and colleagues used propensity matching to examine the risk of incident/recurrent CVD or death, incident CVD, and incident heart failure by antihypertensive class among veterans with HIV and incident hypertension (2000 to 2018).

Of 8,041 veterans, 24, 23, 13, and 11 percent were initiated on angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) monotherapy, thiazide/thiazide-like diuretic monotherapy, ß-blocker monotherapy, and calcium channel blocker monotherapy, respectively. The researchers found that 25 percent experienced a CVD event over a median of 6.5 years. Increased risk of incident CVD was seen in association with ß-blockers but not calcium channel blockers or diuretics compared with ACE inhibitors/ARBs (hazard ratio, 1.90 for ß-blockers); similar hazard ratios were seen for incident/recurrent CVD or death. ACE inhibitors/ARBs were associated with a lower risk of incident heart failure compared with all other classes among veterans without chronic kidney disease (hazard ratios, 1.52, 1.48, and 1.52 for ß-blockers, calcium channel blockers, and diuretics, respectively).

“Patients with HIV need heightened attention to their elevated risk of heart disease,” a coauthor said in a statement. “More dedicated research studying the unique needs for people with HIV and those taking antiretroviral therapies is needed in order to optimize cardiovascular prevention.”

One author disclosed financial ties to the pharmaceutical industry.

You May Also Like::  Tobacco Use Up During Early COVID-19 Lockdown

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.

#dermtwitter
@AADmember

New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More